MedTrace Logo

Dextran 40 Plus Ringer's Lactate Vs. Ringer's Lactate Alone for Fluid Resuscitation in Acute Pancreatitis

NCT06835023 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-02-20

No results posted yet for this study

Summary

This clinical trial aims to learn if a combination of Dextran 40 and Ringer's lactate solution can improve fluid resuscitation in mild and moderate acute pancreatitis (AP) and prevent complications. The main questions it aims to answer are:

Does early fluid resuscitation with Dextran 40 plus Ringer's lactate improve patient outcomes compared to Ringer's alone? Does this treatment reduce inflammation, organ failure, and the need for intensive care unit (ICU) admission? Researchers will compare Dextran 40 plus Ringer's lactate to Ringer's alone to see if the combination therapy is more effective in reducing disease severity and complications.

Participants will:

Receive either Dextran 40 plus Ringer's lactate (1:3 ratio) or Ringer's lactate alone.

Have blood tests every 24 hours to measure inflammation and organ function. Be monitored for changes in disease severity, need for ICU admission, and hospitalization duration.

This study will help determine the best fluid resuscitation strategy for treating mild and moderate acute pancreatitis.

Conditions

  • Acute Pancreatitis (AP)
  • Acute Pancreatic Fluid Collection
  • Fluid Resuscitation

Interventions

DRUG

Ringer lactate (RLS)

50 patients will receive only Ringer Lactat

DRUG

Dextran+Ringer Lactat(D+RLS)

50 patients Dextran+RInger Lactat 1:3 ratio

Sponsors & Collaborators

  • Satu Mare County Emergency Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-10
Primary Completion
2025-05-12
Completion
2025-05-12

Countries

  • Romania

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06835023 on ClinicalTrials.gov